DOCSLIB.ORG

1554 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants Chronic Obstructive Pulmonary Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1554 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants Chronic Obstructive Pulmonary Disease 1554 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants Chronic obstructive pulmonary disease. The value of mu- Profile Preparations colytic therapy in chronic obstructive pulmonary disease Clobutinol hydrochloride is a centrally acting cough suppressant Proprietary Preparations (details are given in Part 3) (COPD—p.1112) is controversial. Two studies have reported for non-productive cough (p.1547) that has been given orally in some improvements in lung function in patients with chronic doses of 40 to 80 mg three times daily; it has also been given by Multi-ingredient: Ital.: Localyn. bronchitis given carbocisteine for up to 6 months,1,2 but it ap- subcutaneous, intramuscular, or intravenous injection. However, peared to have no effect on the number of acute exacerbations.1 the EMEA has recommended for its withdrawal due to the risk However, later studies3,4 have reported reductions in the number of QT interval prolongation. Cloperastine (rINN) of acute exacerbations; the number of common colds was also Preparations Cloperastina; Clopérastine; Cloperastinum; HT-11. 1-{2-[(p- lower in the carbocisteine group in one of the studies.4 Carbo- Chloro-α-phenylbenzyl)oxy]ethyl}piperidine. cisteine may also produce some beneficial effects on sputum rhe- Proprietary Preparations (details are given in Part 3) ology.2,5 Arg.: Proking; Silomat†; Austria: Silomat†; Belg.: Silomat†; Braz.: Silo- Клоперастин mat†; Chile: Broncodual; Calfetos; Clobatos†; Cloval; Pulbronc Simple; Si- C H ClNO = 329.9. 1. Grillage M, Barnard-Jones K. Long-term oral carbocisteine ther- lomat†; Cz.: Silomat†; Fin.: Mixtus; Silomat†; Fr.: Silomat†; Ger.: Husten- 20 24 apy in patients with chronic bronchitis: a double blind trial with stiller†; Nullatuss†; Rofatuss†; Silomat†; stas-Hustenstiller N†; Tussed†; Gr.: CAS — 3703-76-2 (cloperastine); 132301-89-4 (levoclop- placebo control. Br J Clin Pract 1985; 39: 395–8. Silomat†; Ital.: Silomat-Fher†; Malaysia: Silomat†; Port.: Silomat†; Singa- erastine). 2. Aylward M, et al. Clinical evaluation of carbocisteine (Mucolex) pore: Silomat†; Thai.: Silomat†; Venez.: Silomat†. ATC — R05DB21. in the treatment of patients with chronic bronchitis: a double- ATC Vet — QR05DB21. blind trial with placebo control. Clin Trials J 1985; 22: 36–44. Multi-ingredient: Arg.: Bronquisedan; Bronquisedan Mucolitico; Braz.: Hytos Plus; Silomat Plus†; Chile: Broncodual Compuesto; Cloval Com- 3. Allegra L, et al. Prevention of acute exacerbations of chronic puesto; Pulbronc; Solvanol; Tusabron; Vapoflu; Fr.: Silomat†; Indon.: Silo- obstructive bronchitis with carbocysteine lysine salt monohy- mat Compositum; S.Afr.: Silomat DA†; UAE: Orcinol; Venez.: Silomat drate: a multicenter, double-blind, placebo-controlled trial. Res- Compositum†. piration 1996; 63: 174–80. N 4. Yasuda H, et al. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pul- O monary disease. J Am Geriatr Soc 2006; 54: 378–80. Clofedanol Hydrochloride (BANM, rINNM) 5. Braga PC, et al. Identification of subpopulations of bronchitic patients for suitable therapy by a dynamic rheological test. Int J Chlophedianol Hydrochloride (USAN); Clofédanol, Chlorhydrate Clin Pharmacol Res 1989; IX: 175–82. de; Clofedanoli Hydrochloridum; Hidrocloruro de clofedanol; Preparations SL-501. 2-Chloro-α-(2-dimethylaminoethyl)benzyl alcohol hy- Proprietary Preparations (details are given in Part 3) drochloride. Arg.: Mucolitic; Salvitos; Belg.: Bronchathiol†; Muco Rhinathiol; Mu- Клофеданола Гидрохлорид Cl costeine†; Romilar Mucolyticum; Siroxyl; Soludril Expectorans; Braz.: Car- bocin; Carbofan; Carbotoss; Carboxil†; Certuss; Fluitoss; Fluizan†; Mucocis; C17H20ClNO,HCl = 326.3. Mucocistein; Mucofan; Mucoflux; Mucolab; Mucolisil; Mucolitic; Mucolix; CAS — 791-35-5 (clofedanol); 511-13-7 (clofedanol hy- Mucotoss; Chile: Coldin; Cz.: Fenorin; Mucopront†; Pectodrill; Rhinathiol†; drochloride). Cloperastine Fendizoate (rINNM) Fin.: Reodyn; Toclapekt†; Fr.: Actifed Expectorant†; Bronchathiol; Bron- ATC — R05DB10. chokod; Broncoclar; Broncorinol Expectorant†; Bronkirex†; Codotussyl Ex- Clopérastine, Fendizoate de; Cloperastine Hydroxyphenylben- pectorant; Dimotapp Expectorant†; Drill Expectorant; Ergix; Exotoux; Flu- ATC Vet — QR05DB10. zoyl Benzoic Acid; Cloperastine Phendizoate; Cloperastini Fend- ditec; Fluvic; Humex Expectorant; Muciclar; Pectosan Expectorant; izoas; Fendizoato de cloperastina. Pharmakod expectorant; Rhinathiol; Sirop des Vosges Expectorant†; So- lutricine Expectorant†; Toclase Expectorant†; Tussilene†; Ger.: Muco- Cl Клоперастина Фендизоат CH3 pront†; Sedotussin muco†; Transbronchin; Gr.: Allstam; Bronchiole†; Cefla- C20H24ClNO,C20H14O4 = 648.2. vit†; Chilvax; Divalio†; Duxil; Ectofus; Estival; Mucorem†; Mucothiol; CAS — 85187-37-7 (cloperastine fendizoate); 220329- Pneumol; Pulmoclase; Santamex-Expectorant†; Santamex†; Trusil; Hong N Kong: Fluifort; Mucospect; Purasol; Rhinathiol; Solmux; Hung.: Drill Expec- 19-1 (levocloperastine fendizoate). torant; Fenorin; Mucopront; NeoCitran Expectorant; Rhinathiol; Solucis; In- CH3 ATC — R05DB21. don.: Broncholit; Mucocil; Solmux; Irl.: Benylin Clear Action; Exputex; Mu- OH ATC Vet — QR05DB21. codyne; Mucogen; Mucolex; Pulmoclase; Viscolex; Israel: Mical; Mucolit; Mucomed; Ital.: Broncomucil; Bronx†; Carbocit; Fluifort; Lisomucil; Muco- cis; Mucojet†; Mucolase; Mucostar; Mucotreis; Polifluidil†; Polimucil; Reomu- Cloperastine Hydrochloride (rINNM) cil†; Sinecod Tosse Fluidificante; Solucis; Tossefluid†; Jpn: Mucodyne; Ma- Clopérastine, Chlorhydrate de; Cloperastini Hydrochloridum; laysia: Fluifort; Kastipron; Mucopront†; Pabron Cough; Rhinathiol; SCMC; (clofedanol) Mex.: Arbistin; Mucolin; Neth.: Dampo Solvopect; Mucodyne; Pectocold; Hidrocloruro de cloperastina. Rami Slijmoplossende; Rhinathiol; Philipp.: Abluent; Aflem; Ameustyn; Клоперастина Гидрохлорид Bromycil; Broncocent; Broxytone; Carboflem; Carbosol; Cysdexpel; Emux- Pharmacopoeias. In Jpn. el; Esboxyl; Fayerex; Fluralex; Genecar; Lofenin; Loviscol; Mediphlegm; Per- C20H24ClNO,HCl = 366.3. tussin; Phlegmol; Solmux; Solplem; Trimulex; Westcarbox; Zylotin; Zymelyt- Profile CAS — 14984-68-0. ic; Pol.: Mukolina; PectoDrill; Port.: Drill Mucolitico; Finatux; Mucolex; Clofedanol hydrochloride is a centrally acting cough suppressant ATC — R05DB21. Mucorespiral; Mucorhinathiol Infantil; Mucorhinathiol Mucoral; Pulmiben; for non-productive cough (p.1547) that has been given in oral ATC Vet — QR05DB21. Pulmoclase†; Rus.: Bronchobos (Бронхобос); Fluditec (Флюдитек); Flui- fort (Флуифорт); Mucodin (Мукодин); S.Afr.: Acuphlem; Betaphlem; doses of 25 mg three or four times daily. For children’s doses, see Pharmacopoeias. In Jpn. Bronchette; Co-Flem; Flemex; Flemgo; Flemlite; Lessmusec; Medphlem; Administration in Children, below. Mucocaps†; Mucoflem; Mucoless; Mucolinct; Mucosirop†; Mucospect; Sin- Profile gapore: Mucopront†; Rhinathiol; SCMC; Spain: Actithiol; Anatac; Fluidin Administration in children. The following oral doses of Cloperastine is primarily a centrally acting cough suppressant Mucolitico; Iniston Mucolitico; Mucovital; Pectodrill; Pectox; Viscoteina; clofedanol hydrochloride have been recommended for children: used for non-productive cough (p.1547). It also has some antihis- Switz.: Mephathiol; Mucogeran†; Mucoseptal†; Pectox; Rhinathiol; Tus- • 2 to 6 years: 12.5 mg 3 or 4 times daily santiol; Thai.: Amicof; Bocytin; Carbocter; Carbomed; Cisteine†; Exflem; taminic action. The hydrochloride has been given orally as tab- Flemex; Fluifort; I-Cof; Mucolex; Mucomex; Mucopront†; Muflex; Murhinal; • 6 to 12 years: 12.5 to 25 mg 3 or 4 times daily lets in usual doses of 10 to 20 mg three times daily. Cloperastine Rhinathiol; Rhinex; Siflex; Solmux; Throatsil-CBS; Turk.: Mucocis; Mukoliz; fendizoate is used in oral liquid preparations in equivalent doses. Mukotik; UK: Mucodyne; Venez.: Broxolflem; Cisteinol†; Gulaper; Loganil; Preparations Cloperastine fendizoate 17.7 mg is equivalent to about 10 mg of Loviscol; Mucofar; Mucopront. Proprietary Preparations (details are given in Part 3) cloperastine hydrochloride. Levocloperastine fendizoate has Multi-ingredient: Arg.: Mucolitic Antitusivo†; Polimucil†; Fr.: Rhinathiol Canad.: Ulone; Hong Kong: Coldrin†; Singapore: Coldrin†; Spain: been used similarly. Promethazine; Gr.: Carbozor; Flemagon; Grupozil; Gutman; Mucostein; Gentos†. Pneumol Plus; Polimucil; Respinorm; Sevlenyl; Sobrein; Sorbexyl; Vanesin; ◊ References. Hong Kong: Mucosin; Rhinathiol Promethazine; India: Caceff; Carbomox; Multi-ingredient: Arg.: Bronco Biotaer†; Causalon Bronquial; Cofron; Gentiabron†; Neo-Tosel†; Notozen; Pectoral Hebert; Selectus FN; Torfan 1. Aliprandi P, et al. Levocloperastine in the treatment of chronic Moxycarb-DT†; Ital.: Broncofluid; Keraflex; Libexin Mucolitico; Malaysia: nonproductive cough: comparative efficacy versus standard an- Mucoease Plus; Rhinathiol Promethazine; SCMC Promethazine†; Mex.: H†; Toxam†; Toxambay; Chile: Bauxol; Brontal; Cofron†; Diadicon; Kolibel; Mucolin A; Philipp.: Solmux-Broncho (Reformulated); Port.: Bronquial; Mucobrol. titussive agents. Drugs Exp Clin Res 2004; 30: 133–41. Niflux; Singapore: Rhinathiol Promethazine; Spain: Actithiol Antihist; Preparations Bronquicisteina; Eduprim Mucolitico; Switz.: Rhinathiol Promethazine; Tri- ofan. Proprietary Preparations (details are given in Part 3) Clonazoline Hydrochloride (rINNM) ⊗ Belg.: Lysotossil; Novotossil†; Sekin; Braz.: Seki; Hong Kong: Uncough; Ital.: Cloel; Clofend; Mitituss; Nitossil; Politosse; Privituss;
Load more

Recommended publications
  • IIIHIIIUSOO5304377A Unitedo States Patent 19 (11) Patent Number: 5,304,377 Yamada Et Al
    IIIHIIIUSOO5304377A UnitedO States Patent 19 (11) Patent Number: 5,304,377 Yamada et al. (45) Date of Patent: Apr. 19, 1994 54 PROLONGED RELEASE PREPARATION 4,954,298 9/1990 Yamamoto et al. ................. 264/4.6 AND POLYMERS THEREOF 4,962,091 10/1990 Eppstein et al. ........................ 514/2 75) Inventors: Minoru Yamada; Seiko Ishiguro, both 5,061,492 10/1991 Okada et al. ........................ 424/423 Otokuni, all of Japan 0052510 11/1981 European Pat. Off. 73) Assignee: Sherical4. industries, Ltd., O256726O190833 7/19871/1986 European Pat. Off. a, Japan 0263490 10/1987 European Pat. Off. (21) Appl. No.: 986,299 0281482 3/1988 European Pat. Off. 035.0246 7/1989 European Pat. Off. 22 Filed: Dec. 7, 1992 2-212436 8/1990 Japan. Related U.S. Application Data OTHER PUBLICATIONS 63) continuation of ser. No. 777,170, oct. 16, 1991, aban- Chemical Abstracts, vol. 114/No. 6 (Feb. 11, 1991); doned. Columbus, Ohio; Abstract No. 49615R. 30 Foreign Application Priority Data Primary Ent, S. Sir Mueller & Oct. 16, 1990 (JP) Japan .................................. 2-278037 story Agent, or Firm-Wegner, Cantor, Mueller Aug. 28, 1991 JP Japan .................................. 3.217045 51 Int, Cl. ......................... A61K 9/22; A61K 9/52; ' ABSTRACT A61K 31/74 A polymer for a prolonged release preparation which 52 U.S. Cl. ................................. 424/426; 424/78.08; comprises 424/78.37; 424/434; 424/457; 424/468; (A) a polylactic acid and 424/486; 424/497; 525/450, 514/2 (B) a copolymer of glycolic acid and a hydroxycar 58) Field of Search .................. 424/426, 78.08, 78.37, boxylic acid of general formula 424/434, 457, 468, 486, 497; 525/450; 514/2 (56) References Cited R U.S.
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Non-Pharmacologic Therapies and Airway Clearance Techniques in Bronchiectasis
    Division of Pulmonary, Critical Care and Sleep Medicine NON-PHARMACOLOGIC THERAPIES AND AIRWAY CLEARANCE TECHNIQUES IN BRONCHIECTASIS Ashwin Basavaraj, MD, FCCP Associate Director, NYU Bronchiectasis Program NTM Patient Education Program DC 11/24/2019 October 30, 2019 Financial Disclosure • Insmed - Consultant, Advisory Board (Active) • Hill-Rom – Consultant, Principal investigator on a clinical trial (Active) • COPD foundation grant on airway clearance 2 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 Case presentation • 66 year-old female with a history of prior pneumonia 15 years ago presents with productive cough. • She has mild shortness of breath. No fevers, no hemoptysis. She has gained two pounds over the year. • No other prior medical history, and currently not taking any medications • Initial workup including autoimmune serologies and quantitative immunoglobulin levels were negative. • You check AFB, bacterial and fungal sputum cultures. • She has 2 out 3 cultures positive for MAC. 3 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 4 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 What’s the next best step in management? A) Start 3 drug antibiotic therapy for MAC B) Initiate airway clearance with nebulized hypertonic saline and a positive expiratory pressure device C) Start antibiotics for MAC and initiate airway clearance D) Closely monitor without initiation of treatment 5 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 GOALS OF AIRWAY CLEARANCE Short term goals Long term goals • Provide more effective sputum • Reduce further airway damage by clearance that improves ventilation halting the vicious cycle • Reduce cough and breathlessness • Reduce pulmonary exacerbations • Improve quality of life O’Neill, et al.
    [Show full text]
  • Management of Breathlessness in Patients with Life Limiting Disease
    MANAGEMENT OF BREATHLESSNESS IN PATIENTS WITH LIFE LIMITING DISEASE Helen Armstrong Dr Helen Bonwick Dr Clare Jeffries Dr Martin Ledson Dr Kate Marley Mrs Sue Oakes CURRENT STANDARDS AND GUIDELINES • Current standards and guidleines • Literature review – pharmacological and non- pharmacological • Audit results • Proposed new standards and guidelines • Current management of cough Guidelines Non pharmacological options (Level 4 ) • These are important and should not be overlooked. They may be used alone or in conjunction with medication. • They include – Reassurance and explanation – Use of fan or cool air across face – Adequate positioning of the patient to aid breathing – Breathing exercises and relaxation training – Advice on modifying lifestyle – Acupuncture, aromatherapy and reflexology Guidelines Pharmacological options Benzodiazepines (Level 3) • Benzodiazepines may be useful especially if there is coexisting anxiety and/or fear. • Lorazepam is suggested for episodes of paroxysmal breathlessness. Dose: 0.5mg-1mg sublingually as required (max dose 4mg daily). • In patients unable to tolerate oral medication or those in the dying phase, subcutaneous Midazolam 2.5mg-5mg as required may be appropriate. If effective this can be incorporated into a 24hour subcutaneous infusion via syringe driver. Guidelines Nebulised Medication (Level 4)/(Level 1) NB: The first medication of any nebulised medication, including saline, must be monitored for adverse effect such as bronchospasm. • Nebulised non opioids – Nebulised sodium chloride 0.9% may help as a mucolytic. Consider trial for 24hours. Dose: 5ml via a nebuliser 4 hourly as required. – A trial of nebulised bronchodilator should be considered if there is evidence of airways obstruction (Level 4) commonly prescribed bronchdilators are Salbutamol and Ipratropium Bromide.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Bahrain-Pharma-1444108170.Pdf
    Fill Type of Competition S. No BP Brand Name Therapeutical Class Potency Generic Name/Composition Volume Dosage Name,company, retail price form Each 5 ml contents: Samol 120 ml Salbutamol Sulphate 2mg Salbutamol 1 Anti-Asthmatic agent (Bronchodilator) Each 5ml contains Acefylline piperazine 125mg Pifalin 100 ml Acefylline Piperazine 2 (125mg/5ml) Acefylline Piperazine 45mg, Diphenhydramine Dephicef 100 ml Acefylline Piperazine + Diphenhydramine 3 8mg/5ml Ammonium Chloride 100.00mg , Sodium Clomadrin 100 ml Citrate 60.00mg, Ephedrine HCl 7.00mg, Ammonium Chloride + Sodium Citrate + Ephedrine HCl + Chlorpheniramine Maleate 4 Chlorpheniramine Maleate 2.00mg/5ml Each 5 ml contents: Ambroxol HCl eq. to 100 ml Ambroxol 15mg 5 Ambrol Ambroxol HCl Each 5 ml contents: Ambroxol HCl eq. to Cough and Cold 100 ml Syrup 6 Ambroxol 30mg 7 Dextron 100 ml 15mg/5 ml Dextromethorphan Hbr 8 Gufosil 100 ml 100mg/5 ml Guaifenesin 9 Proligen 120 ml 1.25mg + 30mg/5 ml Triprolodin HCl + Pseudoephedrine HCl 10 Tripodil 120 ml 1.25mg + 30mg + 10mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr 11 Tripogin 120 ml 1.25mg + 30mg + 100 mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Guaifenesin 12 Dexotrin 120 ml 1.25mg +10mg + 7.5mg + 50mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr + Guaifenesin Wild cherry (Prunus serotina) + (myroxylon balsamum) + Mallow (Malva Sylvestris) + Welcosin 120 ml 60mg + 18.75mg + 7.5mg + 7.5mg / 5ml 13 Marshnallow (Althaea officinalis) 14 Ivosil 100 ml Each 5 ml contents: Ivy leaf 15 Hexobim 100 ml 4mg/5mlIvy leaves dried extract (4-8:1, 100%) 100 mg Bromhexine HCl Carbocisteine 2% and 5% (i.e.
    [Show full text]
  • UNIVERSITE DE NANTES Thomas Gelineau
    UNIVERSITE DE NANTES __________ FACULTE DE MEDECINE __________ Année 2011 N° 139 THESE pour le DIPLÔME D’ÉTAT DE DOCTEUR EN MÉDECINE DES de médecine générale par Thomas Gelineau né le 29 janvier 1983 à Cholet __________ Présentée et soutenue publiquement le 06/12/2011 __________ LE RHUME DE L'ENFANT ET SON TRAITEMENT: DECISION PARTAGEE AVEC LES PARENTS D'APRES UN QUESTIONNAIRE __________ Président : Monsieur le Professeur Olivier MALARD Directeur de thèse : Madame le Professeur Jacqueline LACAILLE 1 Table des matières IIntroduction................................................................................................................ 7 IIDéfinition, état des connaissances...........................................................................8 1Le rhume.......................................................................................................................................8 APhysiopathologie............................................................................................................................. 8 aL'origine virale.................................................................................................................................... 8 bLa saisonnalité................................................................................................................................... 8 cL'âge de survenue.............................................................................................................................. 9 dLe sexe..................................................................................................................................................
    [Show full text]
  • Interventions for Cough in Cancer (Review)
    Interventions for cough in cancer (Review) Molassiotis A, Bailey C, Caress A, Brunton L, Smith J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 9 http://www.thecochranelibrary.com Interventions for cough in cancer (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 7 AUTHORS’CONCLUSIONS . 8 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 CHARACTERISTICSOFSTUDIES . 13 DATAANDANALYSES. 33 APPENDICES ..................................... 33 HISTORY....................................... 40 CONTRIBUTIONSOFAUTHORS . 41 DECLARATIONSOFINTEREST . 41 SOURCESOFSUPPORT . 41 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 41 NOTES........................................ 41 Interventions for cough in cancer (Review) i Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Interventions for cough in cancer Alex Molassiotis1, Chris Bailey2, Ann Caress1, Lisa Brunton1, Jacky Smith3 1School of Nursing, Midwifery & Social Work, University of Manchester, Manchester, UK.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 August 2011 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by section 17C of the Acts and Regulations Publication Act 1989 have been made in this reprint. A general outline of these changes is set out in the notes at the end of this reprint, together with other explanatory material about this reprint. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 August 2011 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 12 8 Advertisements for medicines 13 9 Advertisements
    [Show full text]